ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
DE-122 flops in wet AMD trial
March 12, 2020Tracon Pharmaceuticals and Santen have decided to halt development of DE-122 for wet age-related macular degeneration (AMD), after reviewing recently obtained top-line data from the Phase IIa AVANTE clinical study. -
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors
August 06, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases ...
Pharma Sources Insight January 2025
